Bausch Health Companies Inc (BHC) Stock Price, Quote & News

Company Profile

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segm...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 514 744 6792

Website: www.bauschhealth.com

Address:

2150 St. ElzEar Boulevard West, Laval, Canada

89quattro Oct. 27 at 10:28 PM

$BHC WTF! Never in my wildest dreams/nightmares did I ever believe back in August 2020, while listening to Pal Joey and his cohorts at a town hall meeting, that we would still be waiting into the 2026 - 2027 timeframe to "find the key to unlock the value" of our companies.

0 · Reply

vcd103 Oct. 26 at 1:08 AM

$BHC $BLCO RBC had this interesting comment on potential sale timing.. RBC Capital has reiterated its Market Perform rating and US$10 price target on Bausch Health Companies (BHC.NaE) ahead of its third-quarter results. Analyst Douglas Miehm estimates third quarter revenue of US$2.65 billion (vs. cons. US$2.62 billion). Key areas of focus include updates on the ongoing Xifaxan patent litigation and potential policy-related headwinds, Miehm notes. "Additionally, we will look for commentary on management's strategic vision for the BLCO asset. In our view, should a sale of the asset materialize, it would most likely occur in the 2026/2027 time frame."

1 · Reply

BEATOFtheMARKET Oct. 24 at 10:48 PM

$BFS $BHC $BHR $BIB $BIGY 🔥

0 · Reply

Wise2 Oct. 24 at 2:56 PM

$BHC Not sure if that was a buy or a sell?

1 · Reply

FU2 Oct. 24 at 1:59 PM

$BHC that was a big trade. I just bought more. Shoot me please, lol

0 · Reply

CindyH0o Oct. 24 at 7:27 AM

$BHC jaw dropping. J. Paulson latest filing of BHC ownership. $BLCO

2 · Reply

DMoney92 Oct. 23 at 10:06 PM

$BHC Follow the money 💰

1 · Reply

Canuck1867 Oct. 23 at 5:27 PM

$BHC Not a single top 10 Shareholder of BHC has a cost base lower than $7 The question becomes: "Are they all stupid Investors for not having sold or do they have information that gives them comfort with staying long the stock?" Forget about them trading options around their position - these are some big names. Welcome any thoughtful views......

0 · Reply

ChubbRock999 Oct. 22 at 11:57 AM

$BHC if $COO and $BLCO were to merge, would BHC have to approve it?

1 · Reply

vcd103 Oct. 22 at 12:00 AM

$BHC This is just wrong https://www.gurufocus.com/insider/9158/joseph-c-papa

1 · Reply

Activist Investor Seeks Strategic Overhaul At Contact Lens Maker Cooper, Suggests Merger With Bausch + Lomb

Oct 9, 2025, 7:00 AM EDT - 19 days ago

Bausch Health Announces Results of Special Meeting of Shareholders

Sep 30, 2025, 8:00 AM EDT - 27 days ago

Bausch Health's Aesthetic Business, Solta Medical, Brings Non-Invasive Aesthetic Innovations to National TV

Sep 30, 2025, 7:00 AM EDT - 4 weeks ago

Bausch Health to Announce Third Quarter 2025 Results on October 29

Sep 29, 2025, 8:00 AM EDT - 4 weeks ago

Bausch Health's OraPharma Introduces "OraTalks," a New Podcast Bringing Bold Conversations to Dentistry

Sep 11, 2025, 12:04 PM EDT - 6 weeks ago

Bausch Health: Repricing Continues As Deleveraging Gains Traction

Sep 11, 2025, 8:35 AM EDT - 6 weeks ago

Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio

Sep 11, 2025, 7:00 AM EDT - 6 weeks ago

Bausch + Lomb Announces Publication of enVista Envy™ Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial

Sep 9, 2025, 7:00 AM EDT - 7 weeks ago

Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers

Sep 5, 2025, 8:02 AM EDT - 7 weeks ago

Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage(R) Non-Surgical System

Aug 26, 2025, 8:00 AM EDT - 2 months ago

Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025

DRRX

Aug 21, 2025, 8:02 AM EDT - 2 months ago

Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide Gel), Now Available Through Public Drug Plans of Quebec and Saskatchewan

Aug 18, 2025, 5:48 PM EDT - 2 months ago

Bausch + Lomb board members resign after Icahn agreement ends

Aug 15, 2025, 2:30 PM EDT - 2 months ago

Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes

Aug 12, 2025, 1:02 PM EDT - 2 months ago

Why Bausch Health Stock Surged By Nearly 20%

Aug 7, 2025, 8:00 AM EDT - 2 months ago

Bausch Health Announces 2025 Gastrointestinal Health Scholars Program Winners

Jul 30, 2025, 11:30 PM EDT - 3 months ago

Bausch Health Companies Inc. (BHC) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 4:05 PM EDT - 3 months ago

Bausch Health Announces Second Quarter 2025 Results

Jul 29, 2025, 2:21 PM EDT - 3 months ago

Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout

DRRX

Jul 29, 2025, 7:00 AM EDT - 3 months ago

Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease

DRRX

Jul 29, 2025, 7:00 AM EDT - 3 months ago

Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops

Jul 28, 2025, 9:10 AM EDT - 3 months ago

Bausch Health to Reduce Debt by Approximately $900 Million Using Cash On Hand

Jul 24, 2025, 8:02 AM EDT - 3 months ago

Bausch Health Announces the Appointment of Two New Members to Its Board of Directors

Jul 10, 2025, 5:00 PM EDT - 3 months ago

CORRECTING and REPLACING: Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Nova Scotia and Two Federal Programs

Jul 10, 2025, 4:15 PM EDT - 3 months ago

Bausch Health Appoints New Chief Accounting Officer

Jul 9, 2025, 8:00 AM EDT - 3 months ago

Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Quebec and Two Federal Programs

Jul 7, 2025, 8:00 AM EDT - 4 months ago

Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh "I Wish I Knew" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy Recurrence

Jul 2, 2025, 7:00 AM EDT - 4 months ago

Bausch Health to Announce Second Quarter 2025 Results on July 30

Jun 26, 2025, 4:30 PM EDT - 4 months ago

Bausch + Lomb Announces Closing of Upsized €675 Million Senior Secured Notes Offering and Partial Credit Agreement Refinancing, Including Upsized $2.325 Billion Term Loan Facility

Jun 22, 2025, 5:00 AM EDT - 4 months ago

A Billionaire Trump Supporter Is Buying These Two Stocks

PPTA

Jun 18, 2025, 11:01 AM EDT - 4 months ago

Bausch Health Shares Rise as Nonexecutive Chairperson Paulson Buys $21.2M in Shares

Jun 16, 2025, 4:04 AM EDT - 4 months ago

Repricing Potential Driven By Deleveraging

Jun 4, 2025, 6:59 AM EDT - 5 months ago

Bausch + Lomb Launches Blink® Nourish Lubricating Eye Drops and Blink Boost Lubricating Eye Drops in the United States

May 21, 2025, 9:45 AM EDT - 5 months ago

Facial Injectable Market Forecasts Report 2025-2030, Competitive Analysis of Key Players - Allergan, Bausch Health, Bloomage Biotechnology, and Galderma

May 21, 2025, 6:59 AM EDT - 5 months ago

Bausch + Lomb Launches New LUMIFY® Preservative Free Redness Reliever Eye Drops in the United States

May 14, 2025, 4:15 PM EDT - 5 months ago

Bausch Health Announces 2025 Annual Meeting of Shareholder Results

May 14, 2025, 6:59 AM EDT - 5 months ago

Bausch + Lomb Launches Zenlens® CHROMA HOA™ in the United States

May 7, 2025, 7:00 AM EDT - 6 months ago

Bausch + Lomb Receives European CE Mark Approval for Preloaded LuxLife® Full Range of Vision Intraocular Lens

May 6, 2025, 8:00 AM EDT - 6 months ago

Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization

Apr 30, 2025, 7:51 PM EDT - 6 months ago

Bausch Health Companies Inc. (BHC) Q1 2025 Earnings Call Transcript

Apr 30, 2025, 4:05 PM EDT - 6 months ago

Bausch Health Announces First Quarter 2025 Results

Apr 29, 2025, 8:00 AM EDT - 6 months ago

Bausch Health Announces Health Canada Clearance of Solta Medical's Thermage(R) FLX System

Apr 22, 2025, 9:33 AM EDT - 6 months ago

Bausch Health Learns Icahn Has 34% Economic Interest in Shares

Apr 22, 2025, 8:54 AM EDT - 6 months ago

Bausch Health says Carl Icahn has exposure to about 34% of company's shares

Apr 22, 2025, 7:25 AM EDT - 6 months ago

Bausch Health Announces Filing of Supplement to Proxy Statement

Apr 21, 2025, 7:00 AM EDT - 6 months ago

Bausch + Lomb Reports More Than 100 Million Units of Contacts Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs

Apr 17, 2025, 3:40 PM EDT - 6 months ago

U.S. District Court Grants Summary Judgment in Favor of FDA, Salix, and Teva, and Against Norwich

Apr 14, 2025, 4:30 PM EDT - 7 months ago

Bausch Health Announces Adoption of Shareholder Rights Plan

Apr 10, 2025, 4:15 PM EDT - 7 months ago

Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship Program

Apr 9, 2025, 8:00 AM EDT - 7 months ago

Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Public Drug Plan Coverage of (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris

89quattro Oct. 27 at 10:28 PM

0 · Reply

vcd103 Oct. 26 at 1:08 AM

1 · Reply

BEATOFtheMARKET Oct. 24 at 10:48 PM

$BFS $BHC $BHR $BIB $BIGY 🔥

0 · Reply

Wise2 Oct. 24 at 2:56 PM

$BHC Not sure if that was a buy or a sell?

1 · Reply

FU2 Oct. 24 at 1:59 PM

$BHC that was a big trade. I just bought more. Shoot me please, lol

0 · Reply

CindyH0o Oct. 24 at 7:27 AM

$BHC jaw dropping. J. Paulson latest filing of BHC ownership. $BLCO

2 · Reply

DMoney92 Oct. 23 at 10:06 PM

$BHC Follow the money 💰

1 · Reply

Canuck1867 Oct. 23 at 5:27 PM

0 · Reply

ChubbRock999 Oct. 22 at 11:57 AM

$BHC if $COO and $BLCO were to merge, would BHC have to approve it?

1 · Reply

vcd103 Oct. 22 at 12:00 AM

$BHC This is just wrong https://www.gurufocus.com/insider/9158/joseph-c-papa

1 · Reply

Canuck1867 Oct. 21 at 2:20 PM

$BHC i wonder if Paulson would have sway over Trump to get the reg approval for a COO/BLCO merger.....

0 · Reply

btradingwarehouse Oct. 20 at 5:43 PM

$BHC ...2BULLS... ... ...Morning Champs !!! ... ...Allow me this much: as long is BLCO is under IPO we won't be going anywhere ... ...If I have to define BHC between buy/sell then DO NOT SELL ANY SHARE !!! ... ...Stay safe smart all good smile

1 · Reply

FU2 Oct. 20 at 3:00 PM

$BHC they got her on a short leash. Lets see $5.50..I will add to my position there.

2 · Reply

kbingo12 Oct. 20 at 12:38 AM

$BHC Exclusive: Jana Partners has a stake in medical-devices maker Cooper and plans to urge a deal to combine its contact-lens unit with rival Bausch + Lomb.

0 · Reply

RichardFordemteets Oct. 19 at 8:39 PM

$BHC what a pos lmfao

0 · Reply

LetsgoRandy Oct. 17 at 2:10 PM

$SPY Dan Nikes thinks Market will slowly melt up into Christmas based on market valuation. This is the same guy who lost his shirt on Valent based on "valuation". He still hasn't learned his lesson from Enron and Worldcom. All good until it's not. $UVXY $BHC

1 · Reply

truckersam Oct. 16 at 4:17 PM

$BHC for a nickel I will

0 · Reply

A777 Oct. 16 at 3:48 AM

$BHC classic example of scam. Pump, dump and go.

0 · Reply

Samg3 Oct. 16 at 12:46 AM

$BHC sold most of my positions a while back for a loss. Still hold a few thousand in an Ira. I vowed I will never buy this stock again but I the street doesn't value the 88% Blco ownership. Bought some April 10 calls that should hopefully make me whole if the ever do something with their failed spin. Thank God I went very heavy with the miners earlier this year, made it much easier to forget this dark ticker of my trading past

0 · Reply

MikeWazowski44 Oct. 15 at 3:36 PM

$BHC Very small starter here.

0 · Reply

FU2 Oct. 15 at 12:38 PM

$BHC next stop $5.50. Probably next week. With a well timed hit piece maybe sooner. People said it would not go under $7. The power of options.

0 · Reply

JarvisFlow Oct. 14 at 6:53 PM

RBC Capital has updated their rating for Bausch Health Companies ( $BHC ) to Sector Perform with a price target of 8.5.

1 · Reply

Market Cap	2.30B
Revenue (ttm)	9.63B
Net Income (ttm)	-46.00M
EPS (ttm)	N/A
PE Ratio	1.70
Forward PE	1.78
Profit Margin	-0.48%
Debt to Equity Ratio	147.88

Volume	1,273,500
Avg Vol	1,851,198
Day's Range	N/A - N/A
Shares Out	370.81M
Stochastic %K	55%
Beta	0.43
Analysts	Hold
Price Target	$7.08